Scaling a Retatrutide Program Across Multiple Clinic Locations: What Changes and What Stays the Same

A retatrutide research program that is running well at one location creates a natural question: can it be expanded to additional locations? The answer is yes — but expansion requires specific protocol amendments and operational adjustments that are different from simply opening a new location for a standard clinical service. Here is what changes and what stays the same.

Adding a new location to an existing IRB protocol requires a protocol amendment — a formal submission to the IRB requesting approval to conduct the research at the new site. The amendment must include:

New site information: The name and address of the new location, the name of the site investigator (the physician who will be the Principal Investigator at the new site), and a description of the clinical facilities at the new site.

Site investigator qualifications: The IRB will want to confirm that the site investigator at the new location has the same qualifications as the PI at the original site — CITI training, relevant clinical experience, and familiarity with the protocol.

Site-specific procedures: If the new location has any site-specific procedures that differ from the original site — different laboratory vendors, different shipping arrangements, different monitoring visit structures — these need to be described in the amendment.

Staff training records: The IRB will want confirmation that all study personnel at the new site have completed the required training before the site opens for enrollment.

The amendment process typically takes 2–4 weeks for an independent IRB. Plan accordingly — you cannot begin enrolling patients at the new site until the amendment is approved.

The core protocol — the inclusion and exclusion criteria, the dosing schedule, the monitoring requirements, the consent document, the adverse event reporting procedures — stays the same across all sites. This is actually an advantage: the compliance infrastructure you built for the first site is directly transferable to the new site. You are not starting from scratch.

The supply chain stays the same. Your supplier relationship, your COA requirements, your cold chain standards — all of these apply equally to the new site. The new site needs its own storage equipment and temperature monitoring, but the standards are identical.

The documentation requirements stay the same. Research records at the new site must meet the same standards as research records at the original site. The IRB can audit any site at any time.

The most important decision in expanding to a new site is who will serve as the site investigator. This person is the physician responsible for the conduct of the research at that location. They need to:

• Be licensed to practice medicine in the state where the new site is located
• Have completed CITI training in human subjects research
• Be familiar with the protocol and the compound
• Be available to manage adverse events and protocol deviations as they arise

If you are expanding to a location where you do not have a physician with these qualifications, you need to address that before you submit the amendment. The IRB will not approve a new site without a qualified site investigator.

As you scale across multiple locations, you face a choice between centralized and decentralized operations. A centralized model — where a single research coordinator manages the protocol compliance, adverse event reporting, and IRB communications for all sites — is more efficient and reduces the risk of inconsistent compliance across sites. A decentralized model — where each site manages its own compliance — is more flexible but creates more opportunities for inconsistency.

For most multi-location practices, a hybrid model works best: a centralized research coordinator who manages IRB communications, protocol amendments, and adverse event reporting, with site-level staff who handle the day-to-day patient interactions and documentation.

The revenue scaling math for a retatrutide program is straightforward. If a single-location program generates $15,000–$25,000 per month in revenue from 30–50 active research subjects, a three-location program generates $45,000–$75,000 per month. The incremental cost of adding a site — the amendment fee, the site investigator training, the storage equipment — is modest relative to the revenue opportunity.

The constraint is not the economics. The constraint is finding qualified site investigators and building the operational infrastructure to maintain consistent compliance across multiple sites. Get the first site right before you expand. The compliance culture you establish at the first site will determine the compliance culture at every subsequent site.